The pharmaceutical group MSD has announced a restructuring of its Riom site (Puy-de-Dôme) with 207 job cuts planned. Specialised in the manufacture and packaging of sterile medicines, including eye drops and antibiotics, the plant is one of the main French and even European sites of the American pharmaceutical giant, Merck Sharp & Dohme (MSD).
In addition to the reorganisation, the group has also announced that it is looking for a buyer for this site. This reorganisation is expected to run in two phases. First, a closure of the site's laboratories because, according to the managment, the number of toxicology studies entrusted to the research centre has decreased considerably in recent years. The MSD group is therefore now considering discontinuing this activity. This research centre currently employs 106 people.
Second, the production part would be restructured. In the long term, 101 jobs could be lost in production if this project reaches its target. The reorganisation is now subject to an information-consultation and negotiation process with the site's employee representative bodies, the first meeting of which is scheduled on 20 November 2019.
A previous reorganisation announcement took place in 2014 (385 job cuts) at the MSD French headquarter.